Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

卡培他滨 医学 拉帕蒂尼 转移性乳腺癌 肿瘤科 内科学 打开标签 癌症 乳腺癌 曲妥珠单抗 随机对照试验 结直肠癌
作者
Binghe Xu,Min Yan,Fei Ma,Xichun Hu,Jifeng Feng,Quchang Ouyang,Zhongsheng Tong,Huiping Li,Qingyuan Zhang,Tao Sun,Xian Wang,Yongmei Yin,Ying Cheng,Wěi Li,Yuanting Gu,Qianjun Chen,Jinping Liu,Jing Cheng,Cuizhi Geng,Shukui Qin
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (3): 351-360 被引量:311
标识
DOI:10.1016/s1470-2045(20)30702-6
摘要

Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab.This is an open-label, randomised, controlled, phase 3 trial done at 29 hospitals in China. Patients with pathologically confirmed HER2-positive metastatic breast cancer, aged 18-70 years, who had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had been previously treated with trastuzumab and taxanes were randomly assigned (1:1) to receive oral pyrotinib 400 mg or lapatinib 1250 mg once daily plus oral capecitabine 1000 mg/m2 twice daily on days 1-14 of each 21-day cycle. Randomisation was done via a centralised interactive web-response system with a block size of four or six and stratified by hormone receptor status and previous lines of chemotherapy for metastatic disease. The primary endpoint was progression-free survival according to masked independent central review. Efficacy and safety were assessed in all patients who received at least one dose of the study drugs. Results presented here are from a prespecified interim analysis. This study is registered with ClinicalTrials.gov, NCT03080805.Between July 31, 2017, and Oct 30, 2018, 267 patients were enrolled and randomly assigned. 134 patients received pyrotinib plus capecitabine and 132 received lapatinib plus capecitabine. At data cutoff of the interim analysis on March 31, 2019, median progression-free survival was significantly longer with pyrotinib plus capecitabine (12·5 months [95% CI 9·7-not reached]) than with lapatinib plus capecitabine (6·8 months [5·4-8·1]; hazard ratio 0·39 [95% CI 0·27-0·56]; one-sided p<0·0001). The most common grade 3 or worse adverse events were diarrhoea (41 [31%] in the pyrotinib group vs 11 [8%] in the lapatinib group) and hand-foot syndrome (22 [16%] vs 20 [15%]). Serious adverse events were reported for 14 (10%) patients in the pyrotinib group and 11 (8%) patients in the lapatinib group. No treatment-related deaths were reported in the pyrotinib group and one sudden death in the lapatinib group was considered treatment related.Pyrotinib plus capecitabine significantly improved progression-free survival compared with that for lapatinib plus capecitabine, with manageable toxicity, and can be considered an alternative treatment option for patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy.Jiangsu Hengrui Medicine and National Key R&D Program of China.For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shi完成签到,获得积分10
刚刚
九思发布了新的文献求助10
刚刚
山色青完成签到,获得积分10
1秒前
三胖发布了新的文献求助10
2秒前
2秒前
爱学习的火龙果完成签到,获得积分10
2秒前
3秒前
3秒前
小泥娃完成签到 ,获得积分10
3秒前
5秒前
Dainlyn完成签到,获得积分10
5秒前
6秒前
6秒前
研友_LNMmW8发布了新的文献求助30
7秒前
风逝关注了科研通微信公众号
8秒前
小郑完成签到,获得积分10
9秒前
逗逗发布了新的文献求助10
9秒前
Leo完成签到,获得积分10
10秒前
zhan发布了新的文献求助10
10秒前
量子星尘发布了新的文献求助10
10秒前
CyrusSo524应助奥利给采纳,获得10
11秒前
科研潜水发布了新的文献求助10
12秒前
科研达人发布了新的文献求助10
13秒前
祁i应助1WSQARFGRDSX采纳,获得10
16秒前
uniquellll发布了新的文献求助10
18秒前
Owen应助九思采纳,获得10
18秒前
张雯思发布了新的文献求助10
18秒前
突突突完成签到,获得积分10
18秒前
20秒前
20秒前
逗逗完成签到,获得积分10
20秒前
21秒前
21秒前
可爱的函函应助rita_sun1969采纳,获得30
21秒前
CodeCraft应助诚心尔琴采纳,获得10
22秒前
32完成签到,获得积分10
22秒前
22秒前
22秒前
张雯思发布了新的文献求助10
22秒前
张雯思发布了新的文献求助10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988827
求助须知:如何正确求助?哪些是违规求助? 3531197
关于积分的说明 11252739
捐赠科研通 3269830
什么是DOI,文献DOI怎么找? 1804815
邀请新用户注册赠送积分活动 881915
科研通“疑难数据库(出版商)”最低求助积分说明 809028